MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

导出原文传递

翻译打印收藏纠错

作者： Hegi, Monika E. ^[1] ; Genbrugge, Els ^[2] ; Gorlia, Thierry ^[3] ; Stupp, Roger ^[4] ; Gilbert, Mark R. ^[5] ; Chinot, Olivier L. ^[6] ; Nabors, L. Burt ^[7] ; Jones, Greg ^[8] ; Van Criekinge, Wim ^[9] ; Straub, Josef ^[10] ; Weller, Michael

作者单位： Lausanne Univ Hosp, Neurosurg & Neurosci Res Ctr, Lausanne, Switzerland ^[1] Merck KGaA, Darmstadt, Germany ^[2] MDxHealth, Irvine, CA USA ^[3] Aix Marseille Univ, Hop Timone, AP HP, Marseille, France ^[4] Northwestern Univ, Feinberg Sch Med, Lurie Comprehens Canc Ctr, Malnati Brain Tumor Inst, Chicago ^[5] Univ Hosp Zurich, Dept Neurol, Zurich, Switzerland ^[6] Univ Alabama Birmingham, Birmingham, AL USA ^[7] Univ Ghent, Dept Math Modeling Stat & Bioinformat, Ghent, Belgium ^[8] European Org Treatment & Res Canc EORTC Data Ctr, Brussels, Belgium ^[9] NCI, NIH, Bethesda, MD 20892 USA ^[10]

发布时间 2019-07-27

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical cancer research

2019年25卷6期

1809-1816页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

检索历史清除